Scotia Foscan NDA Amendment Could Get Treatment Benefit In Labeling
Executive Summary
An efficacy amendment to Scotia's Foscan NDA may allow the company to detail a treatment benefit in labeling for the head and neck cancer palliative agent, the firm indicated.